Breast cancer trials recruiting in District of Columbia

All Breast cancer trials nationally

Cities in District of Columbia

Recruiting trials in District of Columbia

• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
  NCT05150691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  NCT06841354 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
  NCT05894239 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
  NCT07062965 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
  NCT07310420 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: Female · District of Columbia: Washington D.C.
• ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
  NCT07007559 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
  NCT07357597 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
  NCT04841148 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Bundled Cancer Screening and Genetic Services Navigation
  NCT07228000 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 74 Years · Sex: Female · District of Columbia: Washington D.C.
• CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
  NCT05130606 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · District of Columbia: Washington D.C.
• Cancer Experience Registry (CER) for Cancer Patients and Caregivers
  NCT02333604 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Circulating Tumor DNA
  NCT06923527 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
  NCT04852887 · Phase: Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• ETHAN - ET for Male BC
  NCT05501704 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · District of Columbia: Washington D.C.
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female · District of Columbia: Washington D.C.
• Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming
  NCT06536881 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · District of Columbia: Washington D.C.
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  NCT01042379 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Identifying Patterns in the Breath of Individuals With Breast Cancer
  NCT06512350 · Phase: Not specified · Ages: 40 Years to 74 Years · Sex: Female · District of Columbia: Washington D.C.
• Improving Genetic Counseling for BRCA+ Mothers
  NCT04258280 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · District of Columbia: Washington D.C.
• Older Breast Cancer Patients: Risk for Cognitive Decline
  NCT03451383 · Phase: Not specified · Ages: 60 Years to 105 Years · Sex: Female · District of Columbia: Washington D.C.
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
  NCT05232916 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
  NCT05827081 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
  NCT06806930 · Phase: Phase 2 · Ages: 21 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
  NCT06551116 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
  NCT05256745 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · District of Columbia: Washington D.C.
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
  NCT05315700 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Study of XB010 in Subjects With Solid Tumors
  NCT06545331 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
  NCT06500481 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
  NCT05780814 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · District of Columbia: Washington D.C.
• The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
  NCT06892275 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 74 Years · Sex: Female · District of Columbia: Washington D.C.